Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014 (2014), Article ID 141260, 4 pages
http://dx.doi.org/10.1155/2014/141260
Case Report

A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions

1Metropolitan Research Center for Blood Disorders (MRC Japan), 1-45-46 Midorigaoka, Chofu, Tokyo 182-0001, Japan
2Department of General Medicine, Shin-Yurigaoka General Hospital, Furusawa Tsuko 255, Asaoku, Kawasaki, Kanagawa 215-0026, Japan
3Department of Hematology, Shin-Yurigaoka General Hospital, Furusawa Tsuko 255, Asaoku, Kawasaki, Kanagawa 215-0026, Japan

Received 17 July 2014; Accepted 23 September 2014; Published 2 October 2014

Academic Editor: Ramon Tiu

Copyright © 2014 Yumi Yamamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Yumi Yamamoto, Akihito Kawashima, Eri Kashiwagi, and Kiyoyuki Ogata, “A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions,” Case Reports in Hematology, vol. 2014, Article ID 141260, 4 pages, 2014. doi:10.1155/2014/141260